6.3 Gout: Pathophysiology & Acute Management

ABIM Internal Medicine Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: The ABIM Exam, Blueprint & Study Strategy

0.1 Exam Format, Question Types & the 2026 Blueprint 0.2 Eligibility, Registration, Fees & Exam-Day Logistics 0.3 Scoring, the Passing Standard & Score Reports 0.4 Building a Blueprint-Weighted Study Plan

2 Chapter 1: Cardiovascular Disease (14% of Exam)

1.1 Ischemic Heart Disease & Acute Coronary Syndromes 1.2 Antithrombotic Therapy, Secondary Prevention & Mechanical Complications of MI 1.3 Atrial Fibrillation, Atrial Flutter & Stroke Prevention 1.4 Supraventricular Tachycardias, Ventricular Arrhythmias & Bradycardias 1.5 Heart Failure: Classification, Staging & Guideline-Directed Medical Therapy 1.6 Device Therapy, HFpEF & the Cardiomyopathies 1.7 Valvular Heart Disease & Endocarditis Prophylaxis 1.8 Pericardial Disease & Acute Aortic Syndromes 1.9 Hypertension: Classification, Diagnosis & Secondary Causes 1.10 Hypertensive Crises & Dyslipidemia 1.11 Adult Congenital Heart Disease & Coarctation of the Aorta 1.12 Syncope: Reflex, Orthostatic & Cardiac Causes 1.13 Cardiac Physical Examination, Murmurs & Antithrombotic Selection

3 Chapter 2: Endocrinology, Diabetes & Metabolism (9% of Exam)

2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy 2.2 Insulin Therapy, Hyperglycemic Emergencies & Chronic Complications 2.3 Thyroid Function Testing & Hypothyroidism 2.4 Thyrotoxicosis, Thyroid Storm & Thyroid Nodules 2.5 Adrenal & Pituitary Disorders 2.6 Hypercalcemia, Hypocalcemia & Disorders of Mineral Metabolism 2.7 Osteoporosis & Paget Disease of Bone 2.8 Ovarian, Testicular & Reproductive Endocrine Disorders 2.9 Hypoglycemia, Endocrine Tumors, Polyglandular Syndromes & Severe Hypertriglyceridemia

4 Chapter 3: Gastroenterology & Hepatology (9% of Exam)

3.1 Esophageal Disease 3.2 Stomach & Duodenal Disease and Gastrointestinal Hemorrhage 3.3 Inflammatory Bowel Disease 3.4 Celiac Disease & Irritable Bowel Syndrome 3.5 Diverticular Disease & Colorectal Cancer Screening 3.6 Viral Hepatitis, Steatotic & Alcohol-Associated Liver Disease 3.7 Cirrhosis & the Complications of Portal Hypertension 3.8 Acute Pancreatitis 3.9 Chronic Pancreatitis & Biliary Tract Disease 3.10 Inherited, Autoimmune & Drug-Induced Liver Disease 3.11 Small Intestinal Disease, Ischemia & Gastrointestinal Complications of HIV

5 Chapter 4: Infectious Disease (9% of Exam)

4.1 Lower Respiratory Tract Infections & Sepsis Syndromes 4.2 Viral Respiratory Pathogens & Tuberculosis 4.3 Central Nervous System Infections 4.4 Skin, Soft Tissue, Bone & Joint Infections 4.5 Infective Endocarditis & Cardiovascular Infection 4.6 Clostridioides difficile & Catheter-Related Bloodstream Infection 4.7 HIV Diagnosis, Antiretroviral Therapy & Prevention 4.8 Opportunistic Infections & Sexually Transmitted Infections 4.9 Fever of Unknown Origin, Neutropenic Fever & Toxic Shock 4.10 Travel-Related Illness, Vector-Borne Disease & Outbreaks 4.11 Infection Prevention, Nosocomial Infection & Postexposure Prophylaxis 4.12 Rheumatic Fever, Poststreptococcal Disease, Enteric & Hepatic Infections

6 Chapter 5: Pulmonary Disease (9% of Exam)

5.1 COPD: Diagnosis, GOLD Classification & Initial Pharmacotherapy 5.2 Interventions That Reduce COPD Mortality & Exacerbation Management 5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus 5.4 Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis 5.5 Sarcoidosis, Hypersensitivity Pneumonitis & Occupational Lung Disease 5.6 Pulmonary Embolism: Diagnosis, Risk Stratification & Anticoagulation 5.7 Pulmonary Hypertension & Sleep-Disordered Breathing 5.8 Acute Respiratory Distress Syndrome & Mechanical Ventilation 5.9 Pleural Disease, Empyema & Pneumothorax 5.10 Bronchiectasis, Cystic Fibrosis & Restrictive Lung Disease 5.11 Evaluation of Cough, Dyspnea, Hemoptysis & the Solitary Pulmonary Nodule

7 Chapter 6: Rheumatology & Orthopedics (9% of Exam)

6.1 Rheumatoid Arthritis: Diagnosis & Systemic Manifestations 6.2 Antirheumatic Pharmacotherapy & the Spondyloarthropathies 6.3 Gout: Pathophysiology & Acute Management 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease 6.5 Osteoarthritis 6.6 Systemic Lupus Erythematosus 6.7 Systemic Sclerosis, Sjogren Syndrome & Inflammatory Myopathies 6.8 The Vasculitides 6.9 Regional Musculoskeletal Syndromes, Back Pain & Sports Injuries 6.10 Other Primary Rheumatic Disorders & Mixed Connective Tissue Disease 6.11 Osteonecrosis & Metabolic Bone Disease

8 Chapter 7: Hematology (6% of Exam)

7.1 Approach to Anemia & the Microcytic Anemias 7.2 Macrocytic, Normocytic & Hemolytic Anemias 7.3 Hemoglobinopathies, Thalassemias & Paroxysmal Nocturnal Hemoglobinuria 7.4 Platelet Disorders, Thrombocytopenia & the Bleeding Patient 7.5 Coagulation Factor Disorders, Thrombophilia & Anticoagulant Reversal 7.6 Acute Leukemias, Chronic Leukemias & Myeloproliferative Neoplasms 7.7 Lymphomas & Plasma Cell Disorders 7.8 Myelodysplastic Syndrome, Myeloproliferative Neoplasms & Porphyria 7.9 Transfusion Medicine & Late Complications of Transplantation

9 Chapter 8: Medical Oncology (6% of Exam)

8.1 Breast, Lung, Colorectal & Prostate Cancer 8.2 Oncologic Emergencies 8.3 Genitourinary & Gynecologic Malignancies 8.4 Head and Neck, Bone & Soft Tissue Cancer and Cancer of Unknown Primary 8.5 Complications of Cancer & Its Treatment 8.6 Cancer Prevention, Survivorship & Psychosocial Care

10 Chapter 9: Nephrology & Urology (6% of Exam)

9.1 Acute Kidney Injury: Staging, Etiology & Urine Microscopy 9.2 Glomerular Disorders & Nephrotic Syndrome 9.3 Nephritic Syndromes, RPGN & Indications for Renal Replacement Therapy 9.4 Chronic Kidney Disease: Staging & Progression Retardation 9.5 Complications of Chronic Kidney Disease: Anemia, CKD-MBD & Acidosis 9.6 Hyponatremia, Hypernatremia & Water Balance 9.7 Potassium Disorders & Systematic Acid-Base Analysis 9.8 Renal Tubular Acidosis & Nephrolithiasis 9.9 Prostate Disorders, Urinary Incontinence & Other Urologic Conditions 9.10 Cystic Kidney Disease, Obstructive Uropathy, Tubulointerstitial Disease & Hematuria

11 Chapter 10: Neurology (4% of Exam)

10.1 Acute Ischemic Stroke: Syndromes & Reperfusion 10.2 Transient Ischemic Attack, Secondary Prevention & Hemorrhagic Stroke 10.3 Headache & Facial Pain 10.4 Seizures, Epilepsy & Movement Disorders 10.5 Multiple Sclerosis & Neuromuscular Junction Disorders 10.6 Motor Neuron Disease & Acute Peripheral Neuropathy 10.7 Cranial Neuropathies & Neuro-Ophthalmology 10.8 Peripheral Neuropathies, CNS Tumors & Other Neurologic Disorders

12 Chapter 11: Psychiatry & Behavioral Health (4% of Exam)

11.1 Major Depressive Disorder & Medical Mimics 11.2 Antidepressant Pharmacotherapy & Treatment-Resistant Depression 11.3 Bipolar Disorder, Mood Stabilizers & Lithium Toxicity 11.4 Anxiety, Stress-Related & Obsessive-Compulsive Disorders 11.5 Alcohol Use Disorder & Withdrawal 11.6 Pharmacotherapy for Alcohol & Opioid Use Disorder 11.7 Toxidromes, Psychiatric Emergencies & Suicide Risk Assessment 11.8 Psychotic, Somatic Symptom, Factitious & Personality Disorders 11.9 Eating Disorders, Sleep Disorders & Sexual Health

13 Chapter 12: Dermatology (3% of Exam)

12.1 Dermatitis, Papulosquamous & Inflammatory Dermatoses 12.2 Acne, Rosacea & Cutaneous Infections 12.3 Herpes Zoster & Autoimmune Blistering Diseases 12.4 Nodules, Tumors & Cutaneous Oncology 12.5 Dermatologic Emergencies & Severe Cutaneous Adverse Reactions 12.6 Pigment Disorders, Alopecia, Nail Disease & Photosensitivity 12.7 Vascular Dermatoses, Environmental Injury & Cutaneous Signs of Systemic Disease

14 Chapter 13: Obstetrics & Gynecology / Women's Health (3% of Exam)

13.1 Contraception, Preconception Care & Teratogenicity 13.2 Hypertensive Disorders of Pregnancy & Gestational Diabetes 13.3 Thyroid Disease & Venous Thromboembolism in Pregnancy 13.4 Menopause & Menopausal Hormone Therapy 13.5 Abnormal Uterine Bleeding, Endometrial Disease & Gynecologic Cancer Screening 13.6 Breast Disorders & Diseases of the Vulva and Vagina 13.7 Menstrual Disorders, Fibroids, Endometriosis & Early Pregnancy Complications

15 Chapter 14: Geriatric Syndromes (3% of Exam)

14.1 Comprehensive Geriatric Assessment & Frailty 14.2 Falls, Gait Assessment & Polypharmacy 14.3 Urinary Incontinence & Pressure Injuries in Older Adults 14.4 Mild Cognitive Impairment, Dementia & Its Subtypes 14.5 Delirium & the Pharmacotherapy of Cognitive Disorders 14.6 Palliative Care, Hospice & Advance Care Planning 14.7 Chronic Wounds, Nutrition, Swallowing, Constipation & Hip Fracture 14.8 Sensory Impairment, Dizziness, Elder Mistreatment & Care Settings

16 Chapter 15: Allergy & Immunology (2% of Exam)

15.1 Anaphylaxis: Recognition & Emergency Management 15.2 Urticaria & Angioedema 15.3 Drug Allergy, Desensitization & Adult Immunodeficiency 15.4 Food Allergy, Insect Venom Hypersensitivity, Serum Sickness & Contrast Reactions 15.5 Rhinitis, Conjunctivitis, Eosinophilic & Mast Cell Disorders

17 Chapter 16: Preventive Medicine, Immunization & Clinical Epidemiology

16.1 The USPSTF Framework & Evidence-Based Cancer Screening 16.2 Cardiovascular & Metabolic Screening and Primary Prevention 16.3 Adult Immunization & Vaccines in Special Populations 16.4 Clinical Epidemiology, Biostatistics & Study Design

18 Chapter 17: Miscellaneous - Ethics, Patient Safety & Quality Improvement (2% of Exam)

17.1 Principles of Bioethics & Decisional Capacity 17.2 Informed Consent, Treatment Refusal & Special Scenarios 17.3 Surrogate Decision-Making, Advance Directives & Confidentiality 17.4 Patient Safety Science, Medical Error & Diagnostic Reasoning 17.5 Quality Improvement Methods, Health Disparities & Health Equity

19 Chapter 18: Perioperative Medicine & Medical Consultation

18.1 Preoperative Cardiovascular Risk Assessment 18.2 Preoperative Pulmonary Risk & Perioperative Medication Management 18.3 Perioperative Anticoagulation, Bridging & Postoperative Complications

20 Chapter 19: Ophthalmology (1% of Exam)

19.1 The Acute Red Eye & Ophthalmic Emergencies 19.2 Painless Vision Loss & Chronic Ophthalmic Disease 19.3 Uveitis, Scleritis & Orbital Disease

21 Chapter 20: Otolaryngology & Dental Medicine (1% of Exam)

20.1 Dizziness, Vertigo & Epistaxis 20.2 Ear Disorders, Hearing Loss & Upper Respiratory Infections 20.3 Oral Cavity, Salivary Gland, Laryngeal & Taste and Smell Disorders

6.3 Gout: Pathophysiology & Acute Management

Key Takeaways Explain This Topic AI

Gout, pseudogout and hydroxyapatite deposition disease are the three enumerated crystal arthropathy topics.

Monosodium urate crystals are needle-shaped and negatively birefringent, appearing yellow when aligned parallel to the polarizer axis.

Serum urate is frequently normal or low during an acute flare, so a normal value does not exclude gout.

Septic arthritis can coexist with crystal disease, so synovial fluid must also be sent for Gram stain and culture.

Colchicine, non-steroidal anti-inflammatory drugs and corticosteroids are all effective for acute flares, and the choice is driven by comorbidity.

Last updated: August 2026

Crystal arthropathies and osteoarthritis represent the most common causes of acute monoarthritis and chronic joint disability encountered in internal medicine. Accurate differentiation through synovial fluid analysis, recognition of secondary underlying metabolic and endocrine disorders, and evidence-based pharmacologic management are core ABIM exam competencies.

• 1. Gout
• Pathophysiology & Triggers

Gout is an autoinflammatory crystal deposition disease resulting from prolonged hyperuricemia , defined as a serum urate concentration exceeding the physiological solubility limit ( >6.8 mg/dL [404 µmol/L] at 37°C). Uric acid is the end product of purine catabolism, catalyzed by xanthine oxidase .

Hyperuricemia Mechanisms:

Underexcretion of Urate (~90% of patients): Impaired renal tubular clearance via URAT1 / GLUT9 transporters, worsened by chronic kidney disease, volume depletion, hypertension, metabolic syndrome, and medications ( thiazide and loop diuretics, low-dose aspirin, cyclosporine, tacrolimus, pyrazinamide, ethambutol ).

Overproduction of Urate (~10% of patients): High-purine diet, excessive alcohol intake, inherited enzyme defects (HPRT deficiency / Lesch-Nyhan syndrome, PRPP synthetase overactivity), myeloproliferative/lymphoproliferative disorders, psoriasis, and tumor lysis syndrome.

NLRP3 Inflammasome Activation: Precipitation of Monosodium Urate (MSU) crystals in the joint space triggers toll-like receptor (TLR2/TLR4) recognition and phagocytosis by synovial macrophages. This activates the NLRP3 inflammasome complex , driving caspase-1 cleavage of pro-IL-1β into active Interleukin-1β (IL-1β) . IL-1β initiates massive endothelial activation and neutrophil recruitment, producing intense, excruciating synovitis.

Acute Flare Triggers: Rapid fluctuations in serum urate levels (either sudden increases OR sudden drops), alcohol ingestion (especially beer due to high purine/guanosine content and liquor; alcohol metabolism generates lactate, which competes with urate for renal excretion), purine-heavy meals (red meat, seafood, organ meats), high-fructose corn syrup beverages, surgical stress, systemic infection, trauma, dehydration, and abrupt initiation or cessation of urate-lowering therapy.

Arthrocentesis & Synovial Fluid Polarized Light Microscopy

Gold Standard: Polarized light microscopy of aspirated synovial fluid remains the definitive diagnostic test.

Microscopy Findings: Needle-shaped, strongly negatively birefringent crystals :

When the crystal's long axis is parallel to the red compensator filter, the crystal appears yellow .

When the crystal's long axis is perpendicular to the compensator, the crystal appears blue .

Synovial Fluid Characteristics: Inflammatory fluid with cloudy/turbid appearance, WBC count typically 2,000 to 50,000/µL (can exceed 100,000/µL in severe acute flares), with >75–90% polymorphonuclear neutrophils (PMNs) .

Board Rule: Always perform Gram stain and bacterial culture on every arthrocentesis aspirate; crystal confirmation does NOT rule out concurrent septic arthritis!

Serum Urate during Acute Flare: Serum uric acid levels may be falsely normal or low in up to 30–40% of patients during an acute gout flare due to inflammatory IL-6 mediated renal uricosuria. A normal serum uric acid level during an acute attack NEVER excludes the diagnosis of gout.

Chronic Tophaceous Gout & Imaging

Tophi: Nodular, chalky aggregates of MSU crystals surrounded by granulomatous chronic foreign-body giant-cell inflammation. Common locations: helix and antihelix of the ear , olecranon bursa , prepatellar bursa , Achilles tendon , and distal interphalangeal joints.

Radiographic Findings: Late manifestation showing punched-out, well-circumscribed periarticular bony erosions with overhanging sclerotic margins ("rat-bite" or "martini-glass" erosions) , with relative preservation of the joint space until end-stage disease.

Dual-Energy CT (DECT): High-sensitivity non-invasive imaging modality that color-codes uric acid crystal deposits (green) in tendons and soft tissues.

Management of Acute Gout Flares

Pharmacotherapy should be initiated within 24 hours of flare onset . Continue therapy until the flare is completely resolved (typically 5–10 days).

Acute Drug Class Dosing Regimen High-Yield Clinical Indications & Cautions

Oral Colchicine 1.2 mg PO at symptom onset, followed by 0.6 mg 1 hour later (total 1.8 mg on day 1), then 0.6 mg daily or BID starting 12 hours later until flare resolution. Mechanism: Binds tubulin, inhibiting microtubule polymerization and neutrophil chemotaxis/inflammasome activation.; Renal Adjustment: Reduce dose if eGFR <30 mL/min.; Contraindications: Severe renal/hepatic impairment; co-administration with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-glycoprotein inhibitors (cyclosporine, verapamil) due to fatal colchicine toxicity (rhabdomyolysis, pancytopenia, neuromyopathy).

NSAIDs Indomethacin 50 mg PO TID, Naproxen 500 mg PO BID, or Celecoxib 400 mg initial then 200 mg BID for 5–7 days. First-line in young, healthy patients without comorbidities.; Contraindications: Chronic kidney disease (CKD stage >=3), active peptic ulcer disease / GI bleeding, decompensated heart failure, cirrhosis, or severe hypertension.

Systemic Glucocorticoids Prednisone 30–40 mg PO daily for 3–5 days, then tapered over 7–10 days; or IV/IM Methylprednisolone. Drug of choice in patients with renal impairment (CKD), heart failure, anticoagulation, or elderly patients where NSAIDs and colchicine are contraindicated.

Intra-Articular Glucocorticoids Triamcinolone acetonide 20–40 mg injected directly into the joint. Ideal for acute monoarticular flares involving an easily accessible large joint (knee, shoulder, ankle) once infection is excluded.

IL-1 Inhibitors Anakinra (100 mg SC daily x 3 days) or Canakinumab . Off-label rescue therapy for refractory, frequent flares in patients with severe contraindications to NSAIDs, colchicine, and steroids.

Loading diagram... Synovial Fluid Differential Diagnosis and Acute Monoarthritis Algorithm

Sections you finish are checked off in the contents.

• Up Next
• 6.4 Urate-Lowering Therapy & Calcium Pyrophosphate Deposition Disease
• Continue learning